DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults

Phase 3

Completed

Conditions: Healthy Volunteers

First Posted Date: 2006-03-13

Last Posted Date: 2011-07-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT00301639

Locations: 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States

Study of SU11248 in Men With Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Sunitinib

First Posted Date: 2006-03-07

Last Posted Date: 2012-12-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT00299741

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel-Deaconess Medical Center, Boston, Massachusetts, United States

Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.

Phase 1

Completed

Conditions: Lymphoma
Multiple Myeloma
Acute Myelogenous Leukemia

First Posted Date: 2006-03-07

Last Posted Date: 2007-04-24

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 12

Registration Number: NCT00299780

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Phase I Study of Sequential Cord Blood Transplants

Phase 1

Completed

Conditions: Lymphoma
Myelodysplastic Syndrome
Leukemia
Multiple Myeloma

First Posted Date: 2006-03-07

Last Posted Date: 2016-05-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 21

Registration Number: NCT00299767

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Risperidone Augmentation in Patients With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: placebo
Drug: Risperidone

First Posted Date: 2006-02-10

Last Posted Date: 2013-10-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 24

Registration Number: NCT00289861

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa

Phase 2

Completed

Conditions: Osteoporosis
Anorexia Nervosa
Osteopenia
Eating Disorders

Interventions: Drug: Placebo for Recombinant Human Growth Hormone
Drug: Recombinant Human Growth Hormone

First Posted Date: 2006-01-30

Last Posted Date: 2020-09-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 21

Registration Number: NCT00283595

Locations: 🇺🇸
Massachusettes General Hospital, Boston, Massachusetts, United States

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

Phase 4

Completed

Conditions: Social Phobia

Interventions: Drug: Sertraline
Drug: Venlafaxine
Drug: Placebo
Drug: Clonazepam

First Posted Date: 2006-01-27

Last Posted Date: 2013-10-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 397

Registration Number: NCT00282828

Locations: 🇺🇸
University of California San Diego, La Jolla, California, United States
🇨🇦
McMaster University Medical Centre Anxiety Disorders Clinic, Hamilton, Ontario, Canada
🇺🇸
Center for Anxiety and Traumatic Stress Disorders, Boston, Massachusetts, United States

Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology

Not Applicable

Completed

Conditions: Hypertension

First Posted Date: 2006-01-16

Last Posted Date: 2013-03-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 84

Registration Number: NCT00277381

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome

First Posted Date: 2006-01-04

Last Posted Date: 2008-03-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT00271804

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients

Phase 1

Withdrawn

Conditions: Chronic Rejection
Kidney Insufficiency

Interventions: Drug: Rituximab

First Posted Date: 2005-12-05

Last Posted Date: 2023-10-23

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00261547

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy